Navigation Links
Amsterdam Molecular Therapeutics Reports Half Year Results 2008
Date:8/13/2008

Conference Call & Webcast Today at 2:00 p.m. CET

AMSTERDAM, August 13 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today reported its results for the first half year of 2008.

Highlights

- Positive results of pivotal trial for Glybera(R) (AMT-011)

for Hyperlipoproteinemia type I

- European patent for treatment of Non-Alcoholic Steatotic

Hepatitis

- License for treatment of Duchenne Muscular Dystrophy from La

Sapienza University, Rome, Italy

- License for prevention of immune response against treatment of

Hemophilia B from 'TIGET", San Raffaele Telethon Gene Therapy Institute,

Milan, Italy

- Collaboration with St. Jude Children's Research Hospital,

Memphis, Tennessee, USA, including license for treatment of Hemophilia B

- GMP manufacturing development: License for raising yields of

production platform from NIH, Bethesda, USA

- Key financial figures in line with guidance

- Cash & cash equivalents of EUR 43.1 million at June 30, 2008

- Independent supervisory board with three new members bringing

extensive knowledge and experience.

Results comparison

AMT's key financial figures are in line with the guidance that the company has given for 2008. The operating loss increased to EUR 9.1 million for the six months ended June 30, 2008, from EUR 7.2 million for the same period in 2007. This difference is primarily due to the increase of research & development costs to EUR 5.8 million from EUR 3.8 million in the same period of 2007. This increase is particularly related to the development work on the company's lead product Glybera(R) (AMT-011) and increased staffing for this and other programs. General and administrative costs decreased slightly to EUR 3.3 million from EUR 3.5 million for the same period in 2007 due to lower share-based payments.


'/>"/>
SOURCE Amsterdam Molecular Therapeutics B.V
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Amsterdam Molecular Therapeutics Part of Next Biotech Index
2. Amsterdam Molecular Therapeutics to Appoint George Morstyn to Supervisory Board
3. Amsterdam Molecular Therapeutics to Appoint Alexander Ribbink to Supervisory Board
4. Amsterdam Molecular Therapeutics Reports Full Year Results 2007
5. Amsterdam Molecular Therapeutics to Appoint Philippe van Holle (Celgene) to Supervisory Board
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
7. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
8. Molecular Biometrics Announces Results of Parkinsons Disease Research and Receipt of Grant From Michael J. Fox Foundation to Advance Diagnostic Technology
9. Dr. George Poste Named Non-Executive Vice Chairman of CDX Holdings, Parent of Caris Diagnostics and Caris Molecular Diagnostics
10. New Turbomolecular Pumping System From Varian, Inc. Delivers Portable, Dry, Ultra-high Vacuum.
11. Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ... September 02, 2015 , ... ... botanical and plant-derived compounds. BCC Research reveals in its new report that ... this market defines the category and generates the most market demand. , ...
(Date:9/2/2015)... , Sept. 2, 2015 Veracyte, Inc. (NASDAQ: ... Anderson , president and chief executive officer, will present ... September 16, 2015 at 10:30 a.m. ET in ... The live audio webcast and subsequent replay may be ... will be available shortly after conclusion of the presentation ...
(Date:9/2/2015)... ... September 02, 2015 , ... ... to aid high-risk surgeries. From vital sign monitoring in ICU to 3D skull ... enables surgeon to make real-time clinical decisions with simultaneous access to high precision ...
(Date:9/2/2015)... England (PRWEB) , ... September 02, 2015 , ... ... drug discovery and life science research, today unveiled Genedata Screener ® version ... for all in-vitro screening brings to market a rich set of new capabilities. ...
Breaking Biology Technology:Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 2Plant-derived Compounds Poised to Assume Greater Role in Global Drug Markets, According to BCC Research 3Veracyte to Present at Morgan Stanley Global Healthcare Conference 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 2Surgical Workstation Powered by 6th Gen. Intel® Core™ Skylake Processors 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 2New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 3New Genedata Screener 13.0 with Support for High Throughput Flow Cytometry and DMPK Unveiled at ELRIG 4
... WILMINGTON, Delaware, November 3 The new market ... (2009 - 2014),published by MarketsandMarkets ( http://www.marketsandmarkets.com ) ... market. It identifies and analyzes,the main market drivers, ... and applications submarkets in different,geographic regions. , ...
... ... key hire. Cindy Larkin has been hired as Director of Client Services. Cindy ... , ... (Vocus) November 3, 2009 -- Leading medical device and life sciences software engineering consulting ...
... of Delaware has won a $4.4 million grant ... Projects Agency (ARPA-E) to lead a multidisciplinary, multi-institutional ... high-performance permanent magnets. Stronger magnets are essential ... information technology, and communications systems in the 21st-century, ...
Cached Biology Technology:MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 2MarketsandMarkets: Global Stem Cell and Advanced Technologies Market Worth US$ 88.3 Billion By 2014 3Medical Device Software Engineering Firm Full Spectrum Software Appoints Cindy Larkin to Director of Client Services 2UD wins $4.4 million to develop next-generation magnets 2
(Date:8/20/2015)... , Aug. 20, 2015   Sensory, ... on improving the user experience and security of ... technologies, today announced that its TrulySecure™ ... authentication software to be FIDO Certified™. ... for compliance with the FIDO UAF (Universal Authentication ...
(Date:8/18/2015)... N.J. , Aug. 18, 2015 /PRNewswire/ ... a key contributor to the Submission Content ... by IRISS, a non-profit forum. Dedicated to the ... provides a neutral platform for industry, vendors, ... share information and work towards a standard ...
(Date:8/12/2015)... MINNETONKA, Minn. , Aug. 12, 2015   ... that supports the entire spectrum of clinical research, is ... ™ , the company,s comprehensive SaaS-based eClinical technology platform, ... growth during the first two quarters of 2015.   ... and second largest quarters measured by contract value sold ...
Breaking Biology News(10 mins):TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3MedNet Solutions Experiences Explosive Corporate Growth 2
... release is available in German . ... have now developed a new strategy for the formation ... have thus been able to fuse the specific biological ... properties of plastics. Polymer-protein hybrid materials may be of ...
... with a particularly aggressive form of breast cancer seem ... combined anthracycline and taxane chemotherapy regimen before surgery, together ... results from the largest multi-centre trial to investigate this ... Breast Cancer Conference (EBCC-6) in Berlin today (Friday) that ...
... Alliance for Lupus Research (ALR) recently announced it will award ... ALR is very proud to announce, during National Minority Health ... has funded more than 100 research projects, and committed more ... says ALR President Barbara Boyts. For a full list of ...
Cached Biology News:Green gel 2Herceptin and chemo improves response rates without major adverse effects in HER2 breast cancer 2The Alliance for Lupus Research announces 2008 grantees 2
Formula variant: With macro- and micronutrients. Physical Form: powder Suitab tst: plant cell culture tested...
BD Falcon 850 cm Smooth-surface TufRol Roller Bottle, tissue-culture treated polystyrene, blow-molded one-piece design, with easy on/off non-vented cap, packed in double bag. (20/ca) Packaging: ...
... Protein Kit is a simple and convenient method ... The kit has been optimized for use with ... used for any fungus species that is susceptible ... procedure effectively generates spheroplasts of yeast cells that ...
... is a pleiotropic cytokine produced by activated ... OSM inhibits the growth of some tumour ... muscle and Kaposis sarcoma cell proliferation, cytokine ... lipoprotein receptor expression on hepatoma cells. Mouse ...
Biology Products: